Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Indigenous Genomics

The Indigenous Genomics Group aims to build Indigenous leadership in genomic and data sciences, precision health, and ethics to improve health equity and the wellbeing of Indigenous people, families and communities.

Airway Epithelial Research

The Airway Epithelial Research Team is investigating the role of the epithelium in the development of airway diseases including asthma, cystic fibrosis and lung transplant rejection.

Research

The cellular effects of estrogen on allergic asthma

The study aims to identify the mechanism for this so that this knowledge can be used to better treat asthma and allergies in both males and females.

Research

Mechanisms of IgE sensitization

This project investigates how cells of the immune system respond to substances to cause allergies to help develop new treatments.

Infectious Disease Implementation Research

The Infectious Disease Implementation Research Team is a multi-disciplinary group researching the best way to implement infectious disease prevention and treatment strategies to improve the wellbeing of children and teenagers.

Research

Closed Loop Study – Day and Night Feasibility Study

A Closed-Loop System will potentially have a major impact upon acute and chronic complications of diabetes as well as upon their quality of life.

Research

“That's not fair on my kid”: Carers' perspectives on sport participation and experiences for children in out-of-home care

Children in out-of-home care participate in less organised sport than children from other household structures, potentially reducing opportunities for improvements in social, developmental, and health outcomes. Despite this, little is known about barriers and facilitators of sport participation for children in care. We aimed to explore carers' perspectives on the influences on children in care's participation and experiences in organised sport.

Research

Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024

Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.